Abzu and ADViRNA are partnering on siRNA therapeutics development

COPENHAGEN, Denmark - Oct. 14, 2025 - PRLog -- ADViRNA is a boutique U.S.-based CRO headquartered in Worcester, Massachusetts, specializing in the design, synthesis, and validation of oligonucleotide therapeutics. They offer fast turnaround times, exceptional flexibility, and seamless collaboration from sequence design to in vivo validation. They're trusted by global leaders in RNA Therapeutics to provide the precision and performance to meet the demands of any project.

Abzu's siRNA design platform enables fast in silico design of new, safer RNA therapeutics. The design platform leverages Abzu's QLattice for modelling drug properties and rigorously screening for potential off-target effects to ensure lead candidates are both active and safe, as well as cross-reactive in the desired species.

Together, the partners will launch two co-owned programs — one in dermatology and one in muscle biology — marking Abzu's transition from service provider to biotech while ADViRNA continues to support clients as a CRO in parallel.

"At ADViRNA, our focus has always been delivering RNAi solutions with speed, flexibility, and precision. This partnership with Abzu allows us to extend that mission into joint asset development, building on the trust we've established with global leaders in RNA therapeutics."

— Alexey Wolfson, PhD, MBA, CEO & CSO, ADViRNA

"ADViRNA has been a trusted partner for Abzu, bringing deep expertise and wet-lab strength. Together we're moving beyond our roles as CROs to co-develop innovative siRNA assets — starting with programs in dermatology and muscle biology. This marks a major step in Abzu's transition from service provider to biotech."

— Martin Kerr, PhD, Head of Business Development & Pharma Partnerships, Abzu

Read more about Abzu at https://www.abzu.ai

Read more about ADViRNA at https://www.advirna.com